Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDC-1001 +/- nivolumab in advanced HER2-expressing solid tumors
NCT04278144Phase 2Terminated
- Sponsor
- Bolt Biotherapeutics
- Start
- Feb 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 2, open-label trial of trastuzumab + imbotolimod in HER2-positive solid tumor, HER2-positive breast cancer, colorectal cancer (CRC) and 2 more (4 arms), sponsored by Bolt Biotherapeutics. Primary endpoints: Incidence of adverse events at 2 years, Dose-limiting toxicities at 21 days and 2 more. Started Feb 2020; status: terminated.
02
Drugs
trastuzumab + imbotolimod
03
Conditions
HER2-positive solid tumorHER2-positive breast cancercolorectal cancer (CRC)gastroesophageal junction cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT04278144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278144.